7 Cooperative UA LSP bought $25.0M of Evommune (EVMN)
Executed Nov 7 2025, disclosed Nov 12 2025, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 12 2025), the stock returned +0.7% (delay-adjusted); from the execution session (Nov 7 2025), -11.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
7 Cooperative UA LSP (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Evommune, Inc. (EVMN). Across 1 priced purchase filing, the average 21-session return was -11.5% from execution and +0.7% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of EVMN (1,562,500 sh × $16.00, as filed), executed Nov 7 2025.
Healthcare · Evommune, Inc. operates as a clinical-stage biotechnology company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→